Somite AI

We envision a future where advanced artificial intelligence empowers the scalable and reliable production of human tissue to transform the landscape of cell therapies. By harnessing cutting-edge AI foundation models, we are creating a new paradigm in biotechnology to address complex diseases like diabetes, obesity, and muscular dystrophies.

Our mission is to drive the next generation of medical innovation through the development of platforms that integrate deep scientific expertise with sophisticated AI, enabling rapid and efficient discovery and manufacturing of novel cell therapies. We are building the foundations of a healthcare revolution powered by data, automation, and collaboration.

At the core of our vision is a commitment to merging AI and biology to open unprecedented opportunities for patients worldwide, ensuring these life-changing therapies are developed faster, safer, and at scale. We are pioneering a future where technology fundamentally redefines the potential and reach of regenerative medicine.

When we first heard about Somite AI's mission to become the "OpenAI of stem cell biology," we'll admit we were skeptical. The biotech world is littered with ambitious promises that never materialize. But after digging into their approach, we're genuinely intrigued by what this team is building.

The Dream Team Behind the Science

What caught our attention immediately was the founding roster. Dr. Micha Breakstone isn't just another biotech entrepreneur—he's the guy who sold Chorus.ai for $575 million, so he knows how to build and scale AI companies. Pair that with Dr. Jonathan Rosenfeld from MIT's Fundamental AI Group and a lineup of Harvard Medical School professors who are all National Academy of Sciences members, and you've got serious credibility.

This isn't a team of academics playing with AI on the side. These are people who understand both the technical complexity of stem cell biology and the business realities of bringing breakthrough therapies to market.

Two Platforms, One Ambitious Vision

Somite's approach centers on two AI platforms: AlphaStem and DeltaStem. AlphaStem creates a feedback loop where therapy development generates data that improves the platform, which then accelerates future therapy creation. Meanwhile, DeltaStem focuses on building what they claim will be the world's largest cell signaling dataset.

We're particularly interested in how these platforms work together. The idea of creating scalable, reliable cell production could be a game-changer for treating diseases like diabetes and muscular dystrophies—conditions where current therapies often fall short.

The Money Talks

With $60 million raised including a $47 million Series A led by Khosla Ventures, Somite has serious backing. The strategic investment from AMD Ventures adds another layer of validation—AMD doesn't throw money at biotech startups unless they see real potential in the AI infrastructure.

What we find encouraging is that this funding came together relatively quickly after their 2023 founding. In today's cautious investment climate, that suggests investors see something genuinely compelling in Somite's approach.

Our Take

Somite AI is tackling one of medicine's biggest challenges: making cell therapies accessible and scalable. While we're still in early days, the combination of proven AI leadership, world-class scientific advisors, and substantial funding creates a foundation for real impact.

The real test will be translating their AI models into actual therapies that reach patients. But if anyone can bridge the gap between cutting-edge AI and practical medical applications, this team has the credentials to make it happen.